Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma

Current Rheumatology Reports

Volumn 18, Issue 1, 2016, Pages 1-11

  Tsujino, Kazuyuki ^a,b   Sheppard, Dean ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Animal models; Autoimmunity; Fibrosis; Inflammation; Systemic sclerosis; Vasculopathy

Indexed keywords

ANGIOTENSIN II; BLEOMYCIN; DNA TOPOISOMERASE; FIBRILLIN 1; FREUND ADJUVANT; MEMBRANE PROTEIN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; REACTIVE OXYGEN METABOLITE; SCL 70 ANTIBODY; TIGHT SKIN 1; TIGHT SKIN 2; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR FRA 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; WNT10B PROTEIN;

ADAPTIVE IMMUNITY; APOPTOSIS; AUTOIMMUNITY; AUTOSOMAL DOMINANT DISORDER; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE SEVERITY; EMBRYO DEVELOPMENT; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY FIBROSIS; LUNG FIBROSIS; MICROARRAY ANALYSIS; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; STIFF SKIN SYNDROME; WHOLE BODY RADIATION; ANIMAL; COMPLICATION; DISEASE MODEL; GENETIC PREDISPOSITION; MOUSE; SCLERODERMA, SYSTEMIC; TRANSGENIC MOUSE;

ANGIOTENSIN II; ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GRAFT VS HOST DISEASE; MICE; MICE, TRANSGENIC; REACTIVE OXYGEN SPECIES; SCLERODERMA, SYSTEMIC;

EID: 84951987004     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-015-0553-9     Document Type: Review

References (87)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940–4.
2. ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Invest Drugs. 2012;21:119–34.
3. Perrin S. Preclinical research: make mouse studies work. Nature. 2014;507:423–5.
4. Asano Y, Sato S. Animal models of scleroderma: current state and recent development. Curr Rheumatol Rep. 2013;15:382.
5. Guldner HH, Szostecki C, Vosberg HP, Lakomek HJ, Penner E, Bautz FA. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I. Chromosoma. 1986;94:132–8.
6. Manoussakis MN, Constantopoulos SH, Gharavi AE, Moutsopoulos HM. Pulmonary involvement in systemic sclerosis. Association with anti-Scl 70 antibody and digital pitting. Chest. 1987;92:509–13.
7. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum. 1988;31:378–85.
8. de Rooij DJ, Van de Putte LB, Habets WJ, Van Venrooij WJ. Marker antibodies in scleroderma and polymyositis: clinical associations. Clin Rheumatol. 1989;8:231–7.
9. Hu PQ, Fertig N, Medsger Jr TA, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 2003;48:1363–73.
10. Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford). 2001;40:1135–40.
11. Muryoi T, Kasturi KN, Kafina MJ, Cram DS, Harrison LC, Sasaki T, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med. 1992;175:1103–9.
12. Kasturi KN, Shibata S, Muryoi T, Bona CA. Tight-skin mouse an experimental model for scleroderma. Int Rev Immunol. 1994;11:253–71.
13. Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature. 2013;503:126–30. In this paper, two kinds of fibrillin 1 gene-mutated mice were generated to determine the mechanisms by which fibrillin 1 mutations cause stiff skin syndrome (SSS) in patients. Both lines of mutant mice phenocopied SSS with increased collagen deposition in the skin, suggesting that they could be good models for evaluating therapeutic interventions. The authors also showed that mutations in the integrin binding domain of fibrillin 1 resulted in the upregulation of α5β1 and αvβ3 integrins in dermal cells, especially plasmacytoid dendritic cells, and that inhibition of TGF-β or αvβ3 or activation of β1 integrins was effective in inhibiting the mutant phenotype. These results thus identified three potential targets for therapeutic intervention in SSS patients and perhaps in patients with cutaneous fibrosis from scleroderma.
14. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 2008;172:1650–63.
15. Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011;63:3575–85.
16. Hu PQ, Hurwitz AA, Oppenheim JJ. Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice. J Rheumatol. 2007;34:2243–52.
17. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44:2653–64.
18. Servettaz A, Guilpain P, Goulvestre C, Chereau C, Hercend C, Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis. 2007;66:1202–9.
19. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol. 2009;182:5855–64.
20. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999;112:456–62.
21. Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. Exp Dermatol. 2005;14:81–95.
22. Braun RK, Ferrick DA, Sterner-Kock A, Kilshaw PJ, Hyde DM, Giri SN. Comparison of two models of bleomycin-induced lung fibrosis in mouse on the level of leucocytes and T cell subpopulations in bronchoalveolar lavage. Comp Haematol Int. 1996;6:141–8.
23. Ishikawa H, Takeda K, Okamoto A, Matsuo S, Isobe K. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J Invest Dermatol. 2009;129:1688–95.
24. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech. 2011;4:318–33.
25. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003;54:29–52.
26. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088–98.
27. Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB. Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med. 1977;87:707–9.
28. Claman HN, Jaffee BD, Huff JC, Clark RA. Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol. 1985;94:73–84.
29. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum. 2004;50:1319–31.
30. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11–34.
31. Brecher P. Angiotensin II and cardiac fibrosis. Trends Cardiovasc Med. 1996;6:193–8.
32. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38:635–8.
33. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal. 2005;7:1346–55.
34. Uhal BD, Li X, Piasecki CC, Molina-Molina M. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol. 2012;44:465–8.
35. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum. 2004;50:216–26.
36. Marut W, Kavian N, Servettaz A, Hua-Huy T, Nicco C, Chereau C, et al. Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade. Arthritis Rheum. 2013;65:1367–77.
37. Stawski L, Han R, Bujor AM, Trojanowska M. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther. 2012;14:R194.
38. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res. 2007;101:441–54.
39. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension. 2004;44:264–70.
40. Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, et al. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther. 2008;10:201.
41. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A. 2008;105:10525–30.
42. Maurer B, Busch N, Jungel A, Pileckyte M, Gay RE, Michel BA, et al. Transcription factor Fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation. 2009;120:2367–76.
43. Biasin V, Marsh LM, Egemnazarov B, Wilhelm J, Ghanim B, Klepetko W, et al. Meprin beta, a novel mediator of vascular remodelling underlying pulmonary hypertension. J Pathol. 2014;233:7–17. The authors performed a microarray analysis and found that meprin 1 is the most upregulated gene in Fra-2 tg lungs at 8 weeks of age. They also showed that meprin 1 expression is localized in vessels in Fra-2 tg lungs and its expression is elevated in the lungs of patients with idiopathic pulmonary arterial hypertension, suggesting a potential role of meprin 1 in primary and secondary pulmonary hypertension.
44. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008;47 Suppl 5:v2–4.
45. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis. 2012;71:1382–7.
46. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009;5:200–6.
47. Verrecchia F, Mauviel A, Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev. 2006;5:563–9.
48. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007;56:334–44.
49. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem. 2003;278:25109–19.
50. Weis-Garcia F, Massague J. Complementation between kinase-defective and activation-defective TGF-beta receptors reveals a novel form of receptor cooperativity essential for signaling. EMBO J. 1996;15:276–89.
51. Brand T, MacLellan WR, Schneider MD. A dominant-negative receptor for type beta transforming growth factors created by deletion of the kinase domain. J Biol Chem. 1993;268:11500–3.
52. Derrett-Smith EC, Dooley A, Gilbane AJ, Trinder SL, Khan K, Baliga R, et al. Endothelial injury in a transforming growth factor beta-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum. 2013;65:2928–39. This paper reported that TBRIIΔk mice develop pulmonary vascular remodeling characterized by medial thickening, perivascular inflammatory cell infiltrates, and increase in right ventricular pressure. Induction of endothelial cell injury further enhances this phenotype. These mice could thus be useful to evaluate the significance of TGF-β-associated signals in SSc with pulmonary arterial hypertension.
53. Iwayama T, Olson LE. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities. Curr Rheumatol Rep. 2013;15:304.
54. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667–76.
55. Olson LE, Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell. 2009;16:303–13.
56. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.
57. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–80.
58. Guo Y, Xiao L, Sun L, Liu F. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res. 2012;61:337–46.
59. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003;162:1495–502.
60. Longo KA, Wright WS, Kang S, Gerin I, Chiang SH, Lucas PC, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem. 2004;279:35503–9.
61. Wei J, Melichian D, Komura K, Hinchcliff M, Lam AP, Lafyatis R, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum. 2011;63:1707–17.
62. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012;64:2734–45.
63. Ben-David Y, Giddens EB, Bernstein A. Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by friend murine leukemia virus. Proc Natl Acad Sci U S A. 1990;87:1332–6.
64. Masuya M, Moussa O, Abe T, Deguchi T, Higuchi T, Ebihara Y, et al. Dysregulation of granulocyte, erythrocyte, and NK cell lineages in Fli-1 gene-targeted mice. Blood. 2005;105:95–102.
65. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem. 2006;281:25259–69.
66. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem. 2001;276:20839–48.
67. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003;163:571–81.
68. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol. 2009;29:425–34.
69. Hart A, Melet F, Grossfeld P, Chien K, Jones C, Tunnacliffe A, et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity. 2000;13:167–77.
70. Spyropoulos DD, Pharr PN, Lavenburg KR, Jackers P, Papas TS, Ogawa M, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol. 2000;20:5643–52.
71. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010;176:1983–98.
72. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol. 1976;82:493–512.
73. Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res. 1996;6:300–13.
74. Menton DN, Hess RA, Lichtenstein JR, Eisen A. The structure and tensile properties of the skin of tight-skin (Tsk) mutant mice. J Invest Dermatol. 1978;70:4–10.
75. Menton DN, Hess RA. The ultrastructure of collagen in the dermis of tight-skin (Tsk) mutant mice. J Invest Dermatol. 1980;74:139–47.
76. Jimenez SA, Millan A, Bashey RI. Scleroderma-like alterations in collagen metabolism occurring in the TSK (tight skin) mouse. Arthritis Rheum. 1984;27:180–5.
77. Wallace VA, Kondo S, Kono T, Xing Z, Timms E, Furlonger C, et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol. 1994;24:1463–6.
78. Bocchieri MH, Henriksen PD, Kasturi KN, Muryoi T, Bona CA, Jimenez SA. Evidence for autoimmunity in the tight skin mouse model of systemic sclerosis. Arthritis Rheum. 1991;34:599–605.
79. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002;109:1453–62.
80. Shibata S, Muryoi T, Saitoh Y, Brumeanu TD, Bona CA, Kasturi KN. Immunochemical and molecular characterization of anti-RNA polymerase I autoantibodies produced by tight skin mouse. J Clin Invest. 1993;92:984–92.
81. Hatakeyama A, Kasturi KN, Wolf I, Phelps RG, Bona CA. Correlation between the concentration of serum anti-topoisomerase I autoantibodies and histological and biochemical alterations in the skin of tight skin mice. Cell Immunol. 1996;167:135–40.
82. Szapiel SV, Fulmer JD, Hunninghake GW, Elson NA, Kawanami O, Ferrans VJ, et al. Hereditary emphysema in the tight-skin (Tsk/+) mouse. Am Rev Respir Dis. 1981;123:680–5.
83. Ito S, Bartolak-Suki E, Shipley JM, Parameswaran H, Majumdar A, Suki B. Early emphysema in the tight skin and pallid mice: roles of microfibril-associated glycoproteins, collagen, and mechanical forces. Am J Respir Cell Mol Biol. 2006;34:688–94.
84. Martorana PA, Wilkinson M, van Even P, Lungarella G. Tsk mice with genetic emphysema. Right ventricular hypertrophy occurs without hypertrophy of muscular pulmonary arteries or muscularization of arterioles. Am Rev Respir Dis. 1990;142:333–7.
85. Christner PJ, Peters J, Hawkins D, Siracusa LD, Jimenez SA. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum. 1995;38:1791–8.
86. Gentiletti J, McCloskey LJ, Artlett CM, Peters J, Jimenez SA, Christner PJ. Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol. 2005;175:2418–26.
87. Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med. 2010;2:23ra20.